Quantcast
Last updated on April 16, 2014 at 14:08 EDT

Latest Soterix Medical Inc. Stories

2014-03-31 08:30:10

NEW YORK, March 31, 2014 /PRNewswire/ -- Soterix Medical Inc. announces receipt of allowance of claims from the U.S. Patent Office for an application covering their system and method of non-invasive neuromodulation using the proprietary High-Definition transcranial Direct Current Stimulation (HD-tDCS) platform. The claims cover a system and method including an array of electrodes positioned on the scalp and energized so as to achieve controlled brain current flow and targeting. The...

2014-03-24 23:23:21

Soterix Medical Inc. announces a multidisciplinary study based at the University of Illinois Beckman Institute to determine if High-Definition tDCS (HD-tDCS) in conjunction with other interventions improves adaptive reasoning and fluid intelligence. High-Definition tDCS is a proprietary technology that allows non-invasive neuromodulation of targeted brain structures to modulate brain excitability and plasticity. New York, NY (PRWEB) March 24, 2014 Soterix Medical Inc. announced today a...

2013-12-02 12:25:34

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- At the NYCneuromodulation 2013 conference, Soterix Medical Inc. , Rogue Resolutions Ltd, and neuroConn GmbH announced the revolutionary MOBILE neuromodulation platform. The product represents yet another collaboration between Soterix Medical Inc. (based in New York City, NY), Rogue Resolutions Ltd (based in Cardiff, UK), and neuroConn (based in Ilmenau, Germany). Leveraging over five years of engineering innovations, the MOBILE neuromodulation...

2013-10-29 12:28:41

NEW YORK, Oct. 29, 2013 /PRNewswire/ -- Soterix Medical Inc. announces today a Phase 3 trial for Major Depressive Disorder (MDD) that will compare Soterix Medical's Transcranial Direct Current Stimulation (tDCS) - Limited Total Energy (LTE) technology against a fully dosed, effective antidepressant Escitalopram oxalate (Lexapro®). The seminal ELECT-TDCS study initiated by Dr. Andre Brunoni of the University of Sao Paulo (cinausp.org) builds on prior work published in 2013 in JAMA...

2013-08-15 08:28:47

NEW YORK, Aug. 15, 2013 /PRNewswire/ -- Soterix Medical, Inc. announces allowance of claims from the U.S. Patent Office for an application covering their system and method of non-invasive neuromodulation using the proprietary High-Definition transcranial Direct Current Stimulation (HD-tDCS) platform. The claims cover a system and method including a wearable apparatus to position an array of electrodes on the surface of the scalp, provide low dose stimulation to the brain using...

2013-02-20 08:28:58

NEW YORK, Feb. 20, 2013 /PRNewswire/ -- Soterix Medical, Inc. is pleased to report positive results of a double-blind, sham-controlled, crossover trial of 18 patients with Fibromyalgia conducted at Harvard Medical School(1). Fibromyalgia is a prevalent chronic pain syndrome characterized by altered pain and sensory processing in the central nervous system, which is often refractory to multiple therapeutic approaches. The Harvard clinical trial examined the effects of the Soterix Medical's...